Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00925301 |
|
Recruitment Status :
Completed
First Posted : June 22, 2009
Results First Posted : October 30, 2018
Last Update Posted : October 30, 2018
|
Sponsor:
Amicus Therapeutics
Information provided by (Responsible Party):
Amicus Therapeutics
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
The primary objective of this study was to compare the effect of migalastat (123 milligrams [mg] of migalastat [equivalent to 150 mg of migalastat hydrochloride]) (migalastat) versus placebo on kidney globotriaosylceramide (GL-3).
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Fabry Disease | Drug: migalastat hydrochloride Drug: Placebo | Phase 3 |
This double-blind, randomized, placebo-controlled study was conducted in 67 participants at 46 sites worldwide. The study consisted of 2 stages and an optional open-label treatment extension phase:
Stage 1 included a screening period of up to 2 months followed by a 6-month treatment period which involved 4 visits to the clinic. Participants were randomized in equal proportions to receive either migalastat or placebo.
After completing the 6-month double-blind phase, all participants entered Stage 2 of the study and received migalastat in an open-label manner. Stage 2 treatment lasted for 6 months and involved up to 4 visits to the clinic.
Participants who completed both Stage 1 and Stage 2 of the study as scheduled were offered the opportunity to participate in an open-label treatment extension phase with migalastat. The open-label treatment extension phase lasted 12 months and involved 2 visits to the clinic. A follow-up visit was undertaken 1 month following completion or discontinuation from the open-label treatment extension. Participants completing the 12-month open-label treatment extension and providing consent to enter a separate long-term extension were not required to complete this follow-up visit.
Study assessments included clinical laboratory tests, 12-lead electrocardiogram, kidney biopsy, kidney function testing, echocardiography, and patient-reported outcomes.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 67 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Investigator) |
| Masking Description: | Sponsor and Assessor were also blinded |
| Primary Purpose: | Treatment |
| Official Title: | A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacodynamics of AT1001 in Patients With Fabry Disease and AT1001-Responsive GLA Mutations |
| Actual Study Start Date : | October 23, 2009 |
| Actual Primary Completion Date : | June 12, 2012 |
| Actual Study Completion Date : | January 29, 2014 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Fabry disease
Drug Information available for:
Migalastat Hydrochloride
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Migalastat
Migalastat 150-mg capsule taken orally every other day (QOD) for 6 months and an open-label 6-month treatment extension, followed by an optional, 12-month, open-label treatment extension.
|
Drug: migalastat hydrochloride
Oral capsule QOD
Other Names:
|
|
Placebo Comparator: Placebo
Placebo capsule taken orally QOD for 6 months.
|
Drug: Placebo
Oral capsule QOD |
Primary Outcome Measures :
- Percentage Of Participants With At Least A 50% Reduction From Baseline To Month 6 In The Average Number Of Kidney Interstitial Capillary (IC) Globotriaosylceramide (GL-3) Inclusions [ Time Frame: Baseline, Month 6 ]Renal biopsies were taken at Baseline and Month 6 (Stage 1). The specimens were evaluated using virtual microscopy. The annotation, scoring, and adjudication of the kidney histology assessments were performed by the Clinical Pathology Endpoints Committee. The number of kidney IC GL-3 inclusions was assessed by 3 renal pathologists who were blinded to treatment assignments, participants' data, and biopsy sequence. One pathologist served as annotator and identified the 300 capillaries on up to 8 slides per specimen to be scored. Two pathologists served as scorers; these pathologists completed the blinded paired assessments. Each pathologist served as annotator/adjudicator for 1/3 of the cases. Paired assessments were undertaken at Baseline and Month 6. Assessments were made using digital images. A responder was defined as a participant with a ≥50% reduction from Baseline to Month 6 in the average number of kidney IC GL-3 inclusions.
Secondary Outcome Measures :
- Percent Change In Kidney IC GL-3 Inclusions From Baseline To Month 6 [ Time Frame: Baseline, Month 6 ]Renal biopsies were taken at Baseline and Month 6. The specimens were evaluated using virtual microscopy. The annotation, scoring, and adjudication of the kidney histology assessments were performed by the Clinical Pathology Endpoints Committee. The number of kidney IC GL-3 inclusions was assessed by 3 renal pathologists who were blinded to treatment assignments, participants' data, and biopsy sequence. One pathologist served as annotator and identified the 300 capillaries on up to 8 slides per specimen to be scored. Two pathologists served as scorers; these pathologists completed the blinded paired assessments. Each pathologist served as annotator/adjudicator for 1/3 of the cases. Paired assessments were undertaken at Baseline and Month 6. Assessments were made using digital images.
- Change From Baseline Through Month 24 In Urine GL-3 Levels [ Time Frame: Baseline, Months 6, 12, and 24 ]The effect of migalastat versus placebo on urine GL-3 levels was measured by liquid chromatography-mass spectrometry/mass spectrometry. The 24-hour urine samples were collected at Baseline, Month 6 (Stage 1), Month 12 (Stage 2), and Month 24 (OLE). Results are presented as changes in nanograms (ng)/mg creatinine from Baseline to the end of the 3 stages.
Other Outcome Measures:
- Change From Month 6 To Month 12 In Average Number Of Kidney IC GL-3 Inclusions [ Time Frame: Month 6, Month 12 ]Renal biopsies were taken at Month 6 and Month 12. The specimens were evaluated using virtual microscopy. The annotation, scoring, and adjudication of the kidney histology assessments were performed by the Clinical Pathology Endpoints Committee. The number of kidney IC GL-3 inclusions was assessed by 3 renal pathologists who were blinded to treatment assignments, participants' data, and biopsy sequence. One pathologist served as annotator and identified the 300 capillaries on up to 8 slides per specimen to be scored. Two pathologists served as scorers; these pathologists completed the blinded paired assessments. Each pathologist served as annotator/adjudicator for 1/3 of the cases. Paired assessments were undertaken at Month 6 and Month 12. Assessments were made using digital images.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 16 Years to 74 Years (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Male or female between the ages of 16 and 74 diagnosed with Fabry disease.
- Confirmed mutant form of α-galactosidase A shown to be responsive to migalastat in vitro.
- Participant has never been treated with enzyme replacement therapy (ERT) or has not received ERT for 6 consecutive months or longer before the screening visit for the study.
- Urine GL-3 ≥4 times the upper limit of normal at screening.
- Participants taking angiotensin converting enzyme inhibitors or angiotensin receptor blockers must be on a stable dose for a minimum of 4 weeks before the baseline visit.
- Females who can become pregnant and all males agree to be sexually abstinent or use medically accepted methods of birth control during the study and for 30 days after study completion.
- Participant is willing and able to provide written informed consent and assent, if applicable.
Exclusion Criteria:
- Participant has undergone or is scheduled to undergo kidney transplantation, or is currently on dialysis.
- Estimated glomerular filtration rate <30 milliliters per minute per 1.73 meters squared (chronic kidney disease Stage 4 or 5) based on the Modification of Diet in Renal Disease equation at screening.
- Pregnant or breast-feeding.
- History of allergy or sensitivity to study medication (including excipients) or other iminosugars (for example, miglustat, miglitol).
- Participant is treated or has been treated with any investigational drug within 30 days of study start.
- Participant is currently treated or has ever been treated with migalastat.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00925301
Locations
| United States, California | |
| Los Angeles, California, United States, 90048 | |
| San Francisco, California, United States, 94143 | |
| United States, Georgia | |
| Decatur, Georgia, United States, 30033 | |
| United States, Illinois | |
| Chicago, Illinois, United States, 60611 | |
| United States, Kansas | |
| Kansas City, Kansas, United States, 66160 | |
| United States, Massachusetts | |
| Boston, Massachusetts, United States, 02114 | |
| United States, Michigan | |
| Grand Rapids, Michigan, United States, 49525 | |
| United States, New York | |
| New York, New York, United States, 10032 | |
| United States, Pennsylvania | |
| Pittsburgh, Pennsylvania, United States, 15224 | |
| United States, Texas | |
| Dallas, Texas, United States, 75226 | |
| United States, Utah | |
| Salt Lake City, Utah, United States, 84132 | |
| United States, Virginia | |
| Springfield, Virginia, United States, 22152 | |
| United States, Washington | |
| Seattle, Washington, United States, 98195 | |
| Argentina | |
| Buenos Aires, Argentina, B1629ODT | |
| Australia | |
| Adelaide, Australia, 5006 | |
| Parkville, Australia, 3050 | |
| Brazil | |
| Porto Alegre, Brazil, 90035-903 | |
| Sao Paulo, Brazil, 14048-900 | |
| Canada, Quebec | |
| Montreal, Quebec, Canada, H4J 1C5 | |
| Denmark | |
| Kobenhavn, Denmark, DK-2100 | |
| Egypt | |
| Cairo, Egypt, 11451 | |
| France | |
| Garches, France, 92380 | |
| Italy | |
| Roma, Italy, 00168 | |
| Poland | |
| Warszawa, Poland, 04-628 | |
| Spain | |
| Barcelona, Spain, 08025 | |
| Zaragoza, Spain, 50009 | |
| Turkey | |
| Ankara, Turkey, 06500 | |
| United Kingdom | |
| Salford, United Kingdom, M6 8HD | |
Sponsors and Collaborators
Amicus Therapeutics
Investigators
| Study Director: | Medical Monitor, Clinical Research | Amicus Therapeutics |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Amicus Therapeutics |
| ClinicalTrials.gov Identifier: | NCT00925301 |
| Other Study ID Numbers: |
AT1001-011 FACETS ( Other Identifier: Amicus Therapeutics ) 2009-013459-31 ( EudraCT Number ) |
| First Posted: | June 22, 2009 Key Record Dates |
| Results First Posted: | October 30, 2018 |
| Last Update Posted: | October 30, 2018 |
| Last Verified: | October 2018 |
Keywords provided by Amicus Therapeutics:
|
Amicus Therapeutics AT1001 Migalastat |
Pharmacokinetics Substrate Galafold |
Additional relevant MeSH terms:
|
Fabry Disease Sphingolipidoses Lysosomal Storage Diseases, Nervous System Brain Diseases, Metabolic, Inborn Brain Diseases, Metabolic Brain Diseases Central Nervous System Diseases Nervous System Diseases Cerebral Small Vessel Diseases Cerebrovascular Disorders |
Vascular Diseases Cardiovascular Diseases Genetic Diseases, X-Linked Genetic Diseases, Inborn Metabolism, Inborn Errors Lipidoses Lipid Metabolism, Inborn Errors Lysosomal Storage Diseases Metabolic Diseases Lipid Metabolism Disorders |